Archives of Medical Research
Volume 41, Issue 4 , Pages 275-280 , May 2010

NAT2 Polymorphism and Gastric Cancer Susceptibility: A Meta-analysis

  • Xu Zhong

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • ,
  • Cao Hui

      Affiliations

    • Department of Radiation Oncology, Chongqing Medical University, Chongqing, China
    • ,
  • Wu Xiao-Ling

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • Corresponding Author InformationAddress reprint requests to: Wu Xiao-Ling, #76 Linjiang Road, Chongqing 400010, PR China; Phone: +86 023 63693325; FAX: +86 023 63711527
    • ,
  • Li Yan

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
    • ,
  • Luo Na

      Affiliations

    • Department of Gastroenterology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

Received 12 April 2010 ,Accepted 2 June 2010.

References 

  1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–2150
  2. Correa P, Haenszel W, Cuello C, et al. A model for gastric cancer epidemiology. Lancet. 1975;2:58–60
  3. Yokozaki H, Yasui W, Tahara E. Genetic and epigenetic changes in stomach cancer. Int Rev Cytol. 2001;204:49–95
  4. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer. 2002;100:249–260
  5. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. J Clin Epidemiol. 2003;56:1–9
  6. Gao L, Nieters A, Brenner H. Meta-analysis: tumour invasion-related genetic polymorphisms and gastric cancer susceptibility. Aliment Pharmacol Ther. 2008;28:565–573
  7. Loh M, Koh KX, Yeo BH, et al. Meta-analysis of genetic polymorphisms and gastric cancer risk: variability in associations according to race. Eur J Cancer. 2009;45:2562–2568
  8. Blum M, Grant DM, McBride W, et al. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193–203
  9. Hickman D, Pope J, Patil SD, et al. Expression of arylamine N-acetyltransferase in human intestine. Gut. 1998;42:402–409
  10. Hein DW, Doll MA, Gray K, et al. Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus. Cancer Res. 1993;53:509–514
  11. De Stefani E, Boffetta P, Mendilaharsu M, et al. Dietary nitrosamines, heterocyclic amines, and risk of gastric cancer: a case-control study in Uruguay. Nutr Cancer. 1998;30:158–162
  12. Hein DW, Rustan TD, Ferguson RJ, et al. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases. Arch Toxicol. 1994;68:129–133
  13. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9:29–42
  14. Zang Y, Doll MA, Zhao S, et al. Functional characterization of single-nucleotide polymorphisms and haplotypes of human N-acetyltransferase 2. Carcinogenesis. 2007;28:1665–1671
  15. Garcia-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet. 2005;366:649–659
  16. Marcus PM, Hayes RB, Vineis P, et al. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol Biomarkers Prev. 2000;9:461–467
  17. Brockton N, Little J, Sharp L, et al. N-acetyltransferase polymorphisms and colorectal cancer: a HuGE review. Am J Epidemiol. 2000;151:846–861
  18. Chen K, Jiang QT, He HQ. Relationship between metabolic enzyme polymorphism and colorectal cancer. World J Gastroenterol. 2005;11:331–335
  19. Ochs-Balcom HM, Wiesner G, Elston RC. A meta-analysis of the association of N-acetyltransferase 2 gene (NAT2) variants with breast cancer. Am J Epidemiol. 2007;166:246–254
  20. Ambrosone CB, Kropp S, Yang J, et al. Cigarette smoking, N-acetyltransferase 2 genotypes, and breast cancer risk: pooled analysis and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2008;17:15–26
  21. Agundez JA. Polymorphisms of human N-acetyltransferases and cancer risk. Curr Drug Metab. 2008;9:520–531
  22. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration; 2009.
  23. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  24. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101
  25. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  26. Katoh T, Boissy R, Nagata N, et al. Inherited polymorphism in the N-acetyltransferase 1 (NAT1) and 2 (NAT2) genes and susceptibility to gastric and colorectal adenocarcinoma. Int J Cancer. 2000;85:46–49
  27. Boissy RJ, Watson MA, Umbach DM, et al. A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma. Int J Cancer. 2000;87:507–511
  28. Ladero JM, Agundez JA, Olivera M, et al. N-acetyltransferase 2 single-nucleotide polymorphisms and risk of gastric carcinoma. Eur J Clin Pharmacol. 2002;58:115–118
  29. Lan Q, Rothman N, Chow WH, et al. No apparent association between NAT1 and NAT2 genotypes and risk of stomach cancer. Cancer Epidemiol Biomarkers Prev. 2003;12:384–386
  30. Suzuki S, Muroishi Y, Nakanishi I, et al. Relationship between genetic polymorphisms of drug-metabolizing enzymes (CYP1A1, CYP2E1, GSTM1, and NAT2), drinking habits, histological subtypes, and p53 gene point mutations in Japanese patients with gastric cancer. J Gastroenterol. 2004;39:220–230
  31. Hong SH, Kim JW, Kim HG, et al. [Glutathione S-transferases (GSTM1, GSTT1 and GSTP1) and N-acetyltransferase 2 polymorphisms and the risk of gastric cancer]. J Prev Med Public Health. 2006;39:135–140
  32. Al-Moundhri MS, Al-Kindi M, Al-Nabhani M, et al. NAT2 polymorphism in Omani gastric cancer patients—risk predisposition and clinicopathological associations. World J Gastroenterol. 2007;13:2697–2702
  33. Boccia S, Sayed-Tabatabaei FA, Persiani R, et al. Polymorphisms in metabolic genes, their combination and interaction with tobacco smoke and alcohol consumption and risk of gastric cancer: a case-control study in an Italian population. BMC Cancer. 2007;7:206
  34. Shen X, Zhang J, Yan Y, et al. Analysis and estimates of the attributable risk for environmental and genetic risk factors in gastric cancer in a Chinese population. J Toxicol Environ Health A. 2009;72:759–766
  35. Zhang YW, Eom SY, Kim YD, et al. Effects of dietary factors and the NAT2 acetylator status on gastric cancer in Koreans. Int J Cancer. 2009;125:139–145
  36. Malik MA, Upadhyay R, Modi DR, et al. Association of NAT2 gene polymorphisms with susceptibility to esophageal and gastric cancers in the Kashmir Valley. Arch Med Res. 2009;40:416–423
  37. Hosseini H, Dovranehgard F, Arveysi S, et al. No association between N-acetyltransferase 2 (NAT2) and risk of diffuse type of gastric cancer. Toxicol Lett. 2009;189:S138
  38. Kobayashi M, Otani T, Iwasaki M, et al. Association between dietary heterocyclic amine levels, genetic polymorphisms of NAT2, CYP1A1, and CYP1A2 and risk of stomach cancer: a hospital-based case-control study in Japan. Gastric Cancer. 2009;12:198–205
  39. Agudo A, Sala N, Pera G, et al. No association between polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the risk of gastric adenocarcinoma in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2006;15:1043–1045
  40. Rouissi K, Ouerhani S, Marrakchi R, et al. Combined effect of smoking and inherited polymorphisms in arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 on bladder cancer in a Tunisian population. Cancer Genet Cytogenet. 2009;190:101–107
  41. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–1169
  42. Johns LE, Houlston RS. N-acetyl transferase-2 and bladder cancer risk: a meta-analysis. Environ Mol Mutagen. 2000;36:221–227
  43. Marcus PM, Vineis P, Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics. 2000;10:115–122
  44. Borlak J, Reamon-Buettner SM. N-acetyltransferase 2 (NAT2) gene polymorphisms in colon and lung cancer patients. BMC Med Genet. 2006;7:58
  45. Raimondi S, Botteri E, Iodice S, et al. Gene-smoking interaction on colorectal adenoma and cancer risk: review and meta-analysis. Mutat Res. 2009;670:6–14
  46. Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab. 2008;9:487–497

PII: S0188-4409(10)00143-8

doi: 10.1016/j.arcmed.2010.06.001

Archives of Medical Research
Volume 41, Issue 4 , Pages 275-280 , May 2010

Article Tools

* Image Usage & Resolution